AN ACT Relating to ensuring timely, efficient, and evidence-based additions to newborn screenings;
SB 5668 revises Washington’s newborn screening laws to make additions to the screening panel more timely, efficient, and evidence-based. The bill states legislative findings about the importance of newborn screening for detecting rare genetic and metabolic disorders early, and it directs the Department of Health and the State Board of Health to use the federal Recommended Uniform Screening Panel as the baseline for the state’s panel. It also preserves the public’s ability to petition for additions to the panel outside the federal process.
The bill requires the State Board of Health to reestablish the newborn screening panel in rule by July 1, 2025, including all conditions already required under state rule and all conditions on the federal panel as of January 1, 2025. For any new condition added to the federal panel, the board must decide within six months whether to add it in Washington, using a feasibility review that considers costs, federal funding, fee changes, implementation timelines, impacts on state health programs, and the availability of screening technology, diagnostic testing, treatment, and intervention. If the board decides to add a condition, it must complete rulemaking within six months.
The bill also updates fee and revenue provisions tied to newborn screening. It authorizes the Department of Health to continue collecting a newborn screening fee from parents or responsible parties, allows the fee to be collected through the birth facility, and creates a newborn screening revenue account in the state treasury. Receipts must be deposited into that account and used only for activities directly related to implementing and administering the newborn screening chapter. The bill also reaffirms reporting requirements for positive screening results and related conditions.
In addition, SB 5668 makes conforming changes to state law governing newborn screening administration and funding, including amendments and reenactments to RCW provisions related to screening tests, reporting, and treasury fund management. It also includes a temporary expiration date and an effective date, indicating the bill is intended to operate as a time-limited policy change while the state updates its screening process.
Overall, the bill appears aimed at modernizing newborn screening policy and speeding adoption of medically supported tests while keeping fiscal and implementation review in place. Because there were no committee transcripts or recorded votes provided, there is no documented legislative debate or vote history to indicate formal support or opposition in the materials supplied.
SB 5668 would change Washington’s newborn screening framework by tying the state panel more closely to the federal Recommended Uniform Screening Panel, imposing deadlines for state review of newly added conditions, and requiring rulemaking to keep the panel current. It creates a dedicated newborn screening revenue account and directs screening receipts to that account for program administration, while also preserving existing reporting obligations and related Department of Health authority. The bill affects parents, birth facilities, laboratories, the Department of Health, the State Board of Health, and state health programs that may be impacted by screening expansions.
The bill’s stated purpose and findings reflect a generally supportive, public-health-oriented approach focused on early detection, evidence-based decision-making, and timely adoption of beneficial newborn screening conditions. The absence of committee transcripts and votes means there is no recorded debate in the provided materials, but the bill text itself suggests an effort to balance expansion of screening with feasibility, cost, and implementation review. Overall sentiment in the available record appears favorable and policy-driven rather than contentious.
The main points of potential contention are the pace and criteria for adding new conditions to the newborn screening panel, and the fiscal implications of expanding screening. The bill requires feasibility reviews that consider costs, federal funding, fee changes, and impacts on state health programs, which suggests concern about affordability and implementation capacity. Another possible point of debate is the preservation of public petition rights versus the structured, evidence-based process led by the State Board of Health. No specific opposing or supporting stakeholders are identified in the provided transcripts or votes because none were included.